EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

NCT03126435 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

218

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreas Cancer
Locally Advanced Pancreatic Cancer
Pancreatic Adenocarcinoma

Interventions

DRUG: EndoTAG-1
DRUG: Gemcitabine

Sponsor

SynCore Biotechnology Co., Ltd.